CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

SPECT and PET in ischemic heart failure A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF) Sex Differences in Cardiovascular Pathophysiology: Why Women Are Overrepresented in Heart Failure With Preserved Ejection Fraction Modifiable lifestyle factors and heart failure: A Mendelian randomization study Impact of Myocardial Scar on Prognostic Implication of Secondary Mitral Regurgitation in Heart Failure Atrial Fibrillation and the Prognostic Performance of Biomarkers in Heart Failure Heart Failure and Atrial Fibrillation, Like Fire and Fury Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure Dilated cardiomyopathy: so many cardiomyopathies! Permanent pacemaker use among patients with heart failure and preserved ejection fraction: Findings from the Acute Decompensated Heart Failure National Registry (ADHERE) National Registry

Original Research2019 May;21(5):665-675.

JOURNAL:Eur J Heart Fail. Article Link

A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)

McMurray JJV, DeMets DL, DAPA-HF Committees and Investigators. Keywords: protocol; heart failure; sodium-glucose co-transporter 2 inhibitor; type 2 diabetes mellitus

FULL TEXT PDF